title: Dendritic cell-derived exosomes for cancer therapy.
abstract: DC-derived exosomes (Dex) are nanometer-sized membrane vesicles that are secreted by the sentinel antigen-presenting cells of the immune system: DCs. Like DCs, the molecular composition of Dex includes surface expression of functional MHC-peptide complexes, costimulatory molecules, and other components that interact with immune cells. Dex have the potential to facilitate immune cell-dependent tumor rejection and have distinct advantages over cell-based immunotherapies involving DCs. Accordingly, Dex-based phase I and II clinical trials have been conducted in advanced malignancies, showing the feasibility and safety of the approach, as well as the propensity of these nanovesicles to mediate T and NK cell-based immune responses in patients. This Review will evaluate the interactions of Dex with immune cells, their clinical progress, and the future of Dex immunotherapy for cancer.
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Pitt
authors.forename: Fabrice
authors.initials: F
authors.lastname: André
authors.forename: Sebastian
authors.initials: S
authors.lastname: Amigorena
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Soria
authors.forename: Alexander
authors.initials: A
authors.lastname: Eggermont
authors.forename: Guido
authors.initials: G
authors.lastname: Kroemer
authors.forename: Laurence
authors.initials: L
authors.lastname: Zitvogel
mesh_terms: D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003713:Dendritic Cells / Q000276:immunology* / Q000473:pathology; D055354:Exosomes / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy / Q000379:methods*; D007694:Killer Cells, Natural / Q000276:immunology / Q000473:pathology; D009369:Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology